retatrutide expanded access program eli lilly gave mysterious to weight loss drug to 79-year-old patient Lilly, with new data, to

Notably, the observed improvements were present regardless of PAP therapy use, highlighting an important adjunct benefit of GLP-1RA and combined therapies to standard of care OSA treatments

Review article: the iron overload syndromes

What labs might help clarify the bigger picture

& Shalet, S

Think of these junctions like the grout between tiles

CJC-1295 (without DAC): Modified for Stability CJC-1295 without DAC adds modifications to GHRH(1-29) to improve stability: Modified amino acid positions specific modifications at multiple positions to slow enzymatic degradation Slightly extended half-life approximately 30 minutes in research models vs sermorelin's 10-20 minutes Modular research design the modifications can be combined with the DAC modification (see below) for further stability CJC-1295 without DAC provides modest improvement over sermorelin but doesn't dramatically extend half-life